8-K: Bio Green Med Solution Preferred Stock Delisted from Nasdaq

Bio Green Med Solution, Inc. announced the delisting of its 6% Convertible Exchangeable Preferred Stock from The Nasdaq Capital Market due to non-compliance with the minimum Market Value of Publicly Held Shares requirement.

Summary

• Bio Green Med Solution, Inc. (BGMS) received a notice from Nasdaq on March 12, 2026, confirming the delisting of its 6% Convertible Exchangeable Preferred Stock (BGMSP).
• The delisting is a result of the Preferred Stock's failure to regain compliance with Nasdaq Listing Rule 5555(a)(4), specifically the requirement to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $1 million.
• The company was initially notified of non-compliance on September 11, 2025, and had until March 10, 2026, to regain compliance.
• BGMS does not intend to appeal Nasdaq's determination.
• Trading of the Preferred Stock is expected to be suspended at the opening of business on March 23, 2026, unless an appeal is requested by March 19, 2026.
• A Form 25-NSE will be filed with the SEC to remove the Preferred Stock from listing and registration on Nasdaq.
• The Preferred Stock is expected to be officially delisted from The Nasdaq Capital Market on or after April 2, 2026.
• The company believes the Preferred Stock may be quoted and traded on the OTC Markets after April 2, 2026.
• The delisting does not affect the company's Common Stock, which continues to be listed on The Nasdaq Capital Market under the symbol BGMS.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development for the preferred stock, as delisting from a major exchange typically reduces liquidity and investor visibility. While the common stock is unaffected, the inability to meet listing standards for a class of securities is generally a bearish signal.

Positives

• The delisting specifically affects the Preferred Stock (BGMSP) and does not impact the company's Common Stock (BGMS), which remains listed on The Nasdaq Capital Market.
• The company anticipates that the Preferred Stock may still be quoted and traded on the OTC Markets after its delisting from Nasdaq.

Negatives

• The 6% Convertible Exchangeable Preferred Stock (BGMSP) will be delisted from The Nasdaq Capital Market.
• The delisting is due to the Preferred Stock's failure to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $1 million.
• Trading of the Preferred Stock is expected to be suspended on March 23, 2026.
• The company does not intend to appeal the delisting decision, indicating a lack of confidence or resources to meet Nasdaq's requirements for the Preferred Stock.

Risks

• The delisting of the Preferred Stock from Nasdaq may reduce its liquidity and investor interest, potentially impacting its market value on the OTC Markets.
• Forward-looking statements in the report involve substantial risks and uncertainties that could cause actual results to differ materially.
• The company's ability to maintain compliance with other Nasdaq listing rules for its Common Stock could be scrutinized following the Preferred Stock delisting.

Future Outlook

The company expects its Preferred Stock to be delisted from The Nasdaq Capital Market on or after April 2, 2026, but anticipates that it may still be quoted and traded on the OTC Markets thereafter. The company explicitly states it does not intend to appeal the delisting determination.

Management Comments

• "The Company does not intend to request an appeal of this determination."

Industry Context

StockSavvy.ai notes that delistings from major exchanges like Nasdaq often signal underlying financial or operational challenges for a company, particularly when related to market capitalization or publicly held share value. While the common stock remains listed, the inability to maintain listing standards for preferred shares can raise questions about the company's overall market standing and investor confidence, potentially impacting its ability to raise capital or attract institutional investors in the future. This event highlights the stringent compliance requirements of major exchanges compared to the more lenient OTC Markets.

Comparison to Industry Standards

• Nasdaq's minimum Market Value of Publicly Held Shares (MVPHS) requirement of $1 million is a standard benchmark for maintaining listing on the exchange. Failure to meet this indicates that the preferred stock's market valuation and liquidity fell below established thresholds, a common reason for delisting across various industries.
• Companies like Bio Green Med Solution, Inc. that fail to meet such requirements often transition to over-the-counter (OTC) markets, which have less stringent listing criteria. This move is comparable to other small-cap companies that struggle with maintaining market capitalization or share price requirements on major exchanges.

Stakeholder Impact

• Shareholders of the 6% Convertible Exchangeable Preferred Stock (BGMSP) will experience reduced liquidity and potentially lower market visibility as the stock moves from Nasdaq to the OTC Markets.
• Shareholders of the Common Stock (BGMS) are not directly impacted by this delisting, as their shares remain listed on The Nasdaq Capital Market, but may face indirect sentiment effects.

Next Steps

• Trading of the Preferred Stock will be suspended on Nasdaq at the opening of business on March 23, 2026.
• A Form 25-NSE will be filed with the SEC to remove the Preferred Stock from listing and registration on Nasdaq.
• The Preferred Stock is expected to be delisted from The Nasdaq Capital Market on or after April 2, 2026.
• The company anticipates the Preferred Stock may be quoted and traded on the OTC Markets after April 2, 2026.

Key Dates

Recommendation

The delisting of the preferred stock from Nasdaq due to non-compliance with market value requirements is a significant negative event for preferred shareholders. The move to the OTC Markets typically results in decreased liquidity and potentially lower valuations. Given the company's decision not to appeal, it signals a lack of commitment or ability to maintain a major exchange listing for this security. Therefore, a 'sell' recommendation for the preferred stock is warranted to mitigate further potential losses in liquidity and value. The common stock, however, is unaffected by this specific event.

Keywords

delisting, Nasdaq, preferred stock, BGMSP, Bio Green Med Solution, MVPHS, OTC Markets, listing compliance, 8-K filing